Annual ECRI List of Top 10 Health Technology Hazards Underscores Critical Need for Vision-Sciences' EndoSheath(R) Technology

Annual ECRI List of Top 10 Health Technology Hazards Underscores Critical Need
for Vision-Sciences' EndoSheath(R) Technology

ORANGEBURG, N.Y., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Vision-Sciences, Inc.
(Nasdaq:VSCI), a leading provider of unique flexible endoscopic products
utilizing its proprietary sterile disposable EndoSheath® technology, announced
today that for the fourth consecutive year, the ECRI Institute listed
"Inadequate Reprocessing of Endoscopes and Surgical Instruments" among the top
ten most dangerous technology hazards.

"Our EndoSheath technology pre-empts the hazard of inadequate reprocessing by
encasing the flexible endoscope in a sterile, protective EndoSheath
micro-barrier," said Howard Zauberman, Interim Chief Executive Officer of
Vision-Sciences, Inc. "After the procedure, the user removes and disposes of
the EndoSheath barrier, and the flexible endoscope is cleaned using our simple
three-step cleaning process.Three recent research studies, one in
cystoscopy^1 and two in the bronchoscopy setting^2, 3, demonstrated that our
technology has a low risk of pathogen transmission and high patient safety.

"We applaud the ECRI Institute for its efforts to focus the attention of the
medical community on the most significant current risks facing the industry.
We continue to work diligently to increase our market share, and hope that
over time the paradigm will shift to where all flexible endoscopic procedures
in the markets we serve employ our 'always ready, always sterile' EndoSheath
technology to protect patients against the hazards of inadequate endoscopic
reprocessing."

The ECRI Institute is a non-profit patient safety organization that publishes
this annual list, available online at www.ecri.org/2014hazards. The Inadequate
Reprocessing hazard is described as follows:

  *Healthcare facilities clean and disinfect thousands of reusable surgical
    instruments and devices every day.
    
  *Flexible endoscopes, in particular, are complex devices with narrow,
    hard-to-clean channels, and are therefore particularly challenging to
    decontaminate or "reprocess" for subsequent use.
    
  *When reprocessing is not performed properly, however, patient
    cross-contamination is possible, potentially leading to the transmission
    of infectious agents and the spread of diseases such as hepatitis C, HIV,
    and tuberculosis.

^1 Peter Hjorth Jørgensen, Slotsbjerg T et al. A microbiological evaluation of
level of disinfection for flexible cystoscopes protected by disposable
endosheaths. BMC Urology 2013, 13:46; DOI:10.1186/1471-2490-13-46. Accessed
online 14 Nov 2013.

^2Scientific poster presented 19 Oct 2013 by Dr. Flavia Petrini, Universita
Gabriele d'Annunzio Chieti-Pescara at the 67th National Congress of the
Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva
(SIAARTI).

^3Lieutenant Colonel Andrew McDonald Johnston et al. Evaluation of a
disposable sheath bronchoscope system for use in the deployed field hospital.
J R Army Med Corps 08/2013; DOI:10.1136/jramc-2013-000125. Accessed online 14
Nov 2013.

The hazards outlined in the ECRI's annual list demonstrate a critical need for
the EndoSheath technology. Vision-Sciences' proprietary reusable flexible
endoscope is combined with a single-use, sterile protective EndoSheath
disposable, which is placed over the patient contact area of the scope: it's
'always ready, always sterile' EndoSheath technology reduces the risk of
cross-contamination associated with the reuse of conventional endoscopes.

This technology allows healthcare providers to perform a rapid, simplified
reprocessing routine after use, avoiding the elaborate high level
disinfection/sterilization routines required by the U.S. Food and Drug
Administration (the "FDA") for conventional endoscopes. The FDA requires that
all conventional flexible endoscopes be reprocessed according to FDA-cleared
manufacturers' regulations and organizational guidelines, whether they are
used in hospitals, clinics or office settings. The EndoSheath technology
enables healthcare professionals to reduce the steps needed to reprocess
flexible endoscopes from approximately 27 to three, thereby saving time and
lowering costs.

The EndoSheath Technology allows for a rapid and less damaging cleaning
process and provides a multitude of benefits to healthcare practitioners, such
as: lower capital equipment investment; less service and maintenance costs of
capital equipment; less staff exposure to toxic chemicals; increased patient
scheduling flexibility and throughput; improved staff productivity; and, a
more practical implementation of endoscopy.

About Vision-Sciences, Inc.

Vision-Sciences, Inc. designs, develops, manufactures and markets products for
flexible endoscopy. The company's unique product lines feature a streamlined
visualization system and proprietary sterile disposable microbial barrier,
known as EndoSheath^® technology, providing users with efficient and cost
effective endoscope turnover while enhancing patient safety.Information about
Vision-Sciences' products is available at www.visionsciences.com.

Vision-Sciences owns the trademarks Vision Sciences^™ and Slide-On^™ and the
registered trademarks EndoSheath^®, EndoWipe^® and The Vision System^®.

The Vision-Sciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3876

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward-looking statements, which are any
statements that are not historical facts. These forward-looking statements are
based on Vision-Sciences' current expectations, and should not be relied upon
as representing its views as of any subsequent date.Forward-looking
statements are subject to a variety of risks and uncertainties that could
cause the Company's actual results to differ materially from the statements
contained herein; risk factors are detailed in the Company's most recent
annual report and other filings with the U.S. Securities and Exchange
Commission. There is no assurance that any future results or events discussed
in these statements will be achieved. The Company does not assume any
obligation to update any forward-looking statements as a result of new
information or future events or developments, except as may be required by
law.

CONTACT: Keith Darragh
         VP, Finance, Principal Accounting Officer,
         and Principal Financial Officer
         Vision-Sciences, Inc.
         (845) 848-1085
         invest@visionsciences.com
        
         Lisa Wilson
         President
         In-Site Communications, Inc.
         (212) 452-2793
         lwilson@insitecony.com

company logo